Literature DB >> 8455186

Rapid detection of Mycoplasma pneumoniae in clinical samples by the polymerase chain reaction.

M Kai1, S Kamiya, H Yabe, I Takakura, K Shiozawa, A Ozawa.   

Abstract

A DNA amplification method was used to detect Mycoplasma pneumoniae in clinical samples. M. pneumoniae 16S ribosomal RNA gene sequences were selected as the amplification target region. The polymerase chain reaction (PCR) with purified DNA fragments as templates yielded an expected 88-bp fragment from M. pneumoniae but not from other Mycoplasma spp. nor from any of the other bacteria assayed. With this method, the 88-bp product specific for M. pneumoniae could be obtained from a minimum of 0.05 pg of M. pneumoniae DNA. Subsequently this PCR technique was used for the detection of M. pneumoniae in throat-swab samples. Twenty-two of 30 culture-positive clinical samples gave positive results in the PCR test. Thirty-two culture-negative clinical samples and 33 samples from healthy volunteers, of which only one was culture-positive, gave negative results in the same PCR test. This PCR method is useful for the direct detection of M. pneumoniae in clinical samples.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8455186     DOI: 10.1099/00222615-38-3-166

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  10 in total

Review 1.  Molecular diagnosis of Mycoplasma pneumoniae respiratory tract infections.

Authors:  K Loens; D Ursi; H Goossens; M Ieven
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

Review 2.  Relevance of nucleic acid amplification techniques for diagnosis of respiratory tract infections in the clinical laboratory.

Authors:  M Ieven; H Goossens
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

3.  Eosinophilic Fasciitis associated with Mycoplasma arginini infection.

Authors:  Pálma Silló; Dóra Pintér; Eszter Ostorházi; Mercedes Mazán; Norbert Wikonkál; Katinka Pónyai; Dmitriy V Volokhov; Vladimir E Chizhikov; Susan Szathmary; Laszlo Stipkovits; Sarolta Kárpáti
Journal:  J Clin Microbiol       Date:  2011-12-21       Impact factor: 5.948

4.  16S rRNA based polymerase chain reaction compared with culture and serological methods for diagnosis of Mycoplasma pneumoniae infection.

Authors:  F J van Kuppeveld; K E Johansson; J M Galama; J Kissing; G Bölske; E Hjelm; J T van der Logt; W J Melchers
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-05       Impact factor: 3.267

5.  Multiplex polymerase chain reaction for the simultaneous detection of Mycoplasma pneumoniae, Chlamydia pneumoniae, and Chlamydia psittaci in respiratory samples.

Authors:  C Y Tong; C Donnelly; G Harvey; M Sillis
Journal:  J Clin Pathol       Date:  1999-04       Impact factor: 3.411

Review 6.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Rapid, sensitive PCR-based detection of mycoplasmas in simulated samples of animal sera.

Authors:  O Dussurget; D Roulland-Dussoix
Journal:  Appl Environ Microbiol       Date:  1994-03       Impact factor: 4.792

8.  Direct PCR enables detection of Mycoplasma pneumoniae in patients with respiratory tract infections.

Authors:  J H Tjhie; F J van Kuppeveld; R Roosendaal; W J Melchers; R Gordijn; D M MacLaren; J M Walboomers; C J Meijer; A J van den Brule
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

9.  Development of a PCR assay to detect mycoplasma contamination in cord blood hematopoietic stem cells.

Authors:  Reza Tabatabaei-Qomi; Mohsen Sheykh-Hasan; Hoda Fazaely; Naser Kalhor; Mahdieh Ghiasi
Journal:  Iran J Microbiol       Date:  2014-08

10.  Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection.

Authors:  Anna C Nilsson; Per Björkman; Kenneth Persson
Journal:  BMC Microbiol       Date:  2008-06-11       Impact factor: 3.605

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.